MTAP and lymphoma: Due to a favorable toxicity profile without significant myelosuppression and encouraging antitumor activity across a variety of solid tumors with MTAP deletion, phase II clinical trials with AMG 193 have been initiated for patients with advanced solid tumors, advanced or metastatic NSCLC, gastrointestinal cancers, and lymphoma [40,41].